Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10605-10616

  Blaney, Joseph E ^a   Wirblich, Christoph ^b   Papaneri, Amy B ^a   Johnson, Reed F ^a   Myers, Carey J ^b   Juelich, Terry L ^c,d   Holbrook, Michael R ^a,c   Freiberg, Alexander N ^c,d   Bernbaum, John G ^a   Jahrling, Peter B ^a   Paragas, Jason ^a   Schnell, Matthias J ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED RABIES VIRUS VACCINE EXPRESSING ZAIRE EBOLA VIRUS GLYCOPROTEIN; INACTIVATED VACCINE; LIVE RABIES VIRUS VACCINE EXPRESSING ZAIRE EBOLA VIRUS GLYCOPROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLA VIRUS; EBOLA VIRUS INFECTION; FILOVIRUS INFECTION; GENETIC PROCEDURES; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES; RABIES VIRUS; REVERSE GENETICS; SURVIVAL; VIRION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; BRAIN; DISEASE MODELS, ANIMAL; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MICE; MICE, INBRED BALB C; RABIES; RABIES VACCINES; RABIES VIRUS; RODENT DISEASES; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRULENCE;

EBOLA VIRUS; MUS; PRIMATES; RABIES VIRUS; ZAIRE EBOLAVIRUS;

EID: 80055058700     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00558-11     Document Type: Article

References (54)

1. Bermejo, M., et al. 2006. Ebola outbreak killed 5000 gorillas. Science 314: 1564.
2. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651-661.
3. Bukreyev, A., et al. 2009. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 383:348-361.
4. Bukreyev, A. A., J. M. Dinapoli, L. Yang, B. R. Murphy, and P. L. Collins. 2010. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 399:290-298.
5. Cenna, J., et al. 2008. Immune modulating effect by a phosphoproteindeleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 26:6405-6414.
6. Cleaveland, S., E. M. Fevre, M. Kaare, and P. G. Coleman. 2002. Estimating human rabies mortality in the United Republic of Tanzania from dog bite injuries. Bull. World Health Organ. 80:304-310.
7. Conzelmann, K. K., J. H. Cox, L. G. Schneider, and H. J. Thiel. 1990. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 175:485-499.
8. DiNapoli, J. M., et al. 2010. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 29:17-25.
9. Ebihara, H., et al. 2006. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2:e73.
10. Faber, M., et al. 2005. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARSCoV) S protein results in the production of high levels of SARS-CoVneutralizing antibodies. J. Gen. Virol. 86:1435-1440.
11. mac251 challenge. Vaccine 28: 299-308.
12. Faul, E. J., C. N. Wanjalla, J. P. McGettigan, and M. J. Schnell. 2008. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 382: 226-238.
13. Foley, H. D., J. P. McGettigan, C. A. Siler, B. Dietzschold, and M. J. Schnell. 2000. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc. Natl. Acad. Sci. U. S. A. 97:14680-14685.
14. Geisbert, T. W., D. G. Bausch, and H. Feldmann. 2010. Prospects for immunisation against Marburg and Ebola viruses. Rev. Med. Virol. 20:344-357.
15. Geisbert, T. W., et al. 2008. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26:6894-6900.
16. Geisbert, T. W., et al. 2009. Single-injection vaccine protects nonhuman primates against Marburg virus and three species of Ebola virus. J. Virol. 83:7296-7304.
17. Gomme, E. A., E. J. Faul, P. Flomenberg, J. P. McGettigan, and M. J. Schnell. 2010. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol. 84:2820-2831.
18. Hensley, L. E., et al. 2010. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebola virus species. PLoS Pathog. 6:e1000904.
19. Johnson, E., N. Jaax, J. White, and P. Jahrling. 1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76:227-236.
20. Knobel, D. L., J. T. du Toit, and J. Bingham. 2002. Development of a bait and baiting system for delivery of oral rabies vaccine to free-ranging African wild dogs (Lycaon pictus). J. Wildl. Dis. 38:352-362.
21. Lee, J. E., et al. 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454:177-182.
22. Lee, J. E., et al. 2008. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda X light chain. J. Mol. Biol. 375:202-216.
23. Le Gouar, P. J., et al. 2009. How Ebola impacts genetics of Western lowland gorilla populations. PLoS One 4:e8375.
24. Leroy, E. M., et al. 2004. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 303:387-390.
25. Mahanty, S., and M. Bray. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4:487-498.
26. McGettigan, J. P., et al. 2001. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J. Virol. 75:4430-4434.
27. McGettigan, J. P., et al. 2006. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology 344:363-377.
28. McGettigan, J. P., et al. 2003. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env expressed from a single rhabdovirus-based vaccine vector genome. J. Virol. 77:10889-10899.
29. McGettigan, J. P., et al. 2003. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol. 77:237-244.
30. McGettigan, J. P., S. Sarma, J. M. Orenstein, R. J. Pomerantz, and M. J. Schnell. 2001. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J. Virol. 75:8724-8732.
31. McKenna, P. M., et al. 2004. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J. Virol. 78:13455-13459.
32. Mebatsion, T., and K. K. Conzelmann. 1996. Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc. Natl. Acad. Sci. U. S. A. 93:11366-11370.
33. Mebatsion, T., S. Finke, F. Weiland, and K. K. Conzelmann. 1997. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90:841-847.
34. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
35. Plotkin, S. A. 1980. Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev. Infect. Dis. 2:433-448.
36. Sanchez, A., T. W. Geisbert, and H. Feldmann. 2007. Filoviridae: Marburg and Ebola viruses, p. 1409-1448. In D. M. Knipe, P. M. Howley, and D. E. Griffin (ed.), Fields virology, 5th ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA.
37. Schnell, M. J., J. P. McGettigan, C. Wirblich, and A. Papaneri. 2010. The cell biology of rabies virus: using stealth to reach the brain. Nat. Rev. Microbiol. 8:51-61.
38. Schnell, M. J., T. Mebatsion, and K. K. Conzelmann. 1994. Infectious rabies viruses from cloned cDNA. EMBO J. 13:4195-4203.
39. Siler, C. A., et al. 2002. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292:24-34.
40. Smith, M. E., et al. 2006. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 353:344-356.
41. Snook, A. E., et al. 2008. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J. Natl. Cancer Inst. 100:950-961.
42. Sullivan, N. J., et al. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684.
43. Sullivan, N. J., J. E. Martin, B. S. Graham, and G. J. Nabel. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7:393-400.
44. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
45. Sun, Y., et al. 2009. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383:12-21.
46. Tan, G. S., et al. 2005. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 331:82-93.
47. Vogel, G. 2007. Conservation. Scientists say Ebola has pushed Western gorillas to the brink. Science 317:1484.
48. Vogel, G. 2006. Ecology. Tracking Ebola's deadly march among wild apes. Science 314:1522-1523.
49. Vos, A., et al. 1999. An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species. Epidemiol. Infect. 123:165-175.
50. Vos, A., E. Pommerening, L. Neubert, S. Kachel, and A. Neubert. 2002. Safety studies of the oral rabies vaccine SAD B19 in striped skunk (Mephitis mephitis). J. Wildl. Dis. 38:428-431.
51. Warfield, K. L., et al. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U. S. A. 100:15889-15894.
52. Warfield, K. L., et al. 2007. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196(Suppl. 2):S430-S437.
53. Wirblich, C., and M. J. Schnell. 2011. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. J. Virol. 85:697-704.
54. World Health Organization. 1993. Report of the Fourth WHO Consultation on Oral Immunization of Dogs against Rabies. WHO/Rab.Res./93.42. WHO, Geneva, Switzerland.